Abstract
Genomewide molecular profiling has revealed new subtypes of lymphoma that originate from lymphocytes that differ in developmental stage and that use distinct oncogenic programs, yet are indistinguishable under the microscope. In this review, we discuss recent progress in the molecular genetics of aggressive lymphomas and focus on the most common form of this disease, diffuse large-B-cell lymphoma, which accounts for 30 to 40% of newly diagnosed lymphomas.
Publication types
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B-Lymphocytes / cytology
-
B-Lymphocytes / metabolism
-
B-Lymphocytes / physiology*
-
Cell Differentiation
-
Gene Expression
-
Humans
-
Lymphoma, Large B-Cell, Diffuse* / classification
-
Lymphoma, Large B-Cell, Diffuse* / drug therapy
-
Lymphoma, Large B-Cell, Diffuse* / genetics
-
Lymphoma, Large B-Cell, Diffuse* / pathology
-
Metabolic Networks and Pathways / drug effects
-
NF-kappa B / metabolism
-
Receptors, Antigen, B-Cell / metabolism
-
Signal Transduction
Substances
-
NF-kappa B
-
Receptors, Antigen, B-Cell